NEW! TransIT-X2® Dynamic Delivery System

A novel, polymeric system for efficient delivery of plasmid DNA and/or siRNA/miRNA

Experience the transfection breakthrough. Achieve superior transfections with an innovative polymeric system that efficiently delivers both DNA and RNA out of the endosome and into the cytoplasm overcoming a critical barrier to nucleic acid delivery. The TransIT-X2® Dynamic Delivery System gives researchers:

icon Efficiency–Exceptional Broad Spectrum Transfection
icon Versatility–Cutting Edge Delivery of Plasmid DNA and siRNA
icon Technology–Novel, Non-Liposomal, Polymeric Delivery

Experimental Data | Frequently Asked Questions | See What Others are Saying about the NEW! TransIT-X2® System

TransIT-X2® System Enables Superior Gene Expression in a Variety of Cell Types

‡ Cell types with >2-fold greater expression in head-to-head comparisons
Click here for cell-type specific transfection protocol recommendations
 
TransIT-X2® Dynamic Delivery System Enables Superior Gene Expression in a Variety of Cell Types. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect plasmid DNA encoding luciferase into 41 different cell types at three reagent-to-DNA ratios. Luciferase expression was compared at 24 hours post-transfection using a standard luciferase assay. Head-to-head comparisons at optimized ratios illustrate superior or equal luciferase expression using TransIT-X2® in 36 of 41 cell types; 17 cell types that had expression levels 2-fold higher are denoted with ‡.
 

Figures and Data

Figure 1: Visualization of High GFP Expression using TransIT-X2® Dynamic Delivery System
Figure 2: High GFP Transfection Efficiency in Multiple Cell Lines and Primary Cells Using TransIT-X2® System
Figure 3: Functional Co-delivery of Plasmid DNA and siRNA using TransIT-X2® System
Figure 4: TransIT-X2® Dynamic Delivery System Achieves Higher Knockdown than Lipofectamine® 2000
Figure 5: Effective miRNA Delivery using TransIT-X2® Yields Decreased Levels of PTK9 mRNA
PREVIOUS NEXT
Figure 1:Visualization of High GFP Expression using TransIT-X2 Dynamic Delivery System
Figure 1. Visualization of High GFP Expression using TransIT-X2® Dynamic Delivery System. TransIT-X2® Dynamic Delivery System was used to transfect plasmid DNA encoding EGFP into A549, CHO-K1, HepG2, LNCaP, MDCK, PC12, primary human mammary epithelial cells (HMEC) and normal human dermal fibroblasts (NHDF). Transfections were performed in 35 mm MatTek dishes using 4-8 µl of TransIT-X2® to deliver 2 µg of DNA. Images (32X) were captured at 48 hours post-transfection using a Zeiss Axiovert S100 inverted fluorescence microscope.

* indicates primary cell types
Figure 2:High GFP Transfection Efficiency in Multiple Cell Lines and Primary Cells Using TransIT-X2 System
Figure 2. High GFP Transfection Efficiency in Multiple Cell Lines and Primary Cells using TransIT-X2® Dynamic Delivery System. TransIT-X2® Dynamic Delivery System was used to transfect plasmid DNA encoding EGFP into A549, CHO-K1, Hep G2, MDCK, LNCaP, PC-12, primary human mammary epithelial cells (HMEC) and normal human dermal fibroblasts (NHDF). Transfections were performed in 96-well plates using 0.2-0.4 µl of TransIT-X2® to deliver 0.1 µg of DNA (2:1, 3:1 or 4:1 reagent: DNA ratio). Triplicate wells were assayed 48 hours post-transfection using guava easyCyte™ 5HT Flow Cytometer.

*indicates primary cell types
Figure 3:Functional Co-delivery of Plasmid DNA and siRNA using TransIT-X2 System
Figure 3. Functional Co-delivery of Plasmid DNA and siRNA using the TransIT-X2® Dynamic Delivery System. TransIT-X2® Dynamic Delivery System was used to transfect plasmid Cy®5 labeled DNA encoding nuclear YFP and Cy®3 labeled siRNA into HeLa cells. Transfection was performed in 6-well plates with Poly-L-Lysine (PLL) coated coverslips using 4 µl of TransIT-X2® to deliver 2 µg of DNA and 25 nM siRNA (2:1 reagent:DNA ratio). Actin cytoskeleton was stained using Alexa Fluor® 350 Phalloidin. Images (63X) were captured at 24 hours post-transfection using a Nikon A1R confocal microscope. Image key: yellow (nuclear YFP), blue (Cy®5 labeled DNA), red (Cy®3 labeled siRNA), green (actin cytoskeleton).
Figure 4:TransIT-X2 Dynamic Delivery System Achieves Higher Knockdown than Lipofectamine 2000
Figure 4. TransIT-X2® Dynamic Delivery System Achieves Higher Knockdown than Lipofectamine® 2000. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect siRNA targeting endogenous proteins – GAPDH and AHA1 or to deliver a non-targeting siRNA control in normal human dermal fibroblasts (NHDF). Cells were transfected in a 6-well plate using 4 µl of TransIT-X2® or 6 µl of Lipofectamine® 2000 and 25 nM siRNA according to each manufacturer's protocol. The amount of GAPDH or AHA1 mRNA was measured relative to 18s rRNA levels using qRT-PCR and then normalized to the mRNA levels of the non-targeting control, 48 hours post-transfection. Error bars represent the standard deviation of triplicate wells.
Figure 5:Effective miRNA Delivery using TransIT-X2 Yields Decreased Levels of PTK9 mRNA
Figure 5. Effective miRNA Delivery using TransIT-X2® Dynamic Delivery System Yields Decreased Levels of PTK9 mRNA. TransIT-X2® Dynamic Delivery System and Lipofectamine® 2000 Transfection Reagent were used to transfect Pre-miR™ hsa-miR-1 miRNA Precursor or mirVana™ miRNA mimic, miR-1, both known to decrease PTK9 mRNA levels. A Pre-miR™ negative control was also transfected to assess baseline mRNA levels. T47D cells were transfected in a 12-well plate using 3 µl of TransIT-X2® or Lipofectamine® 2000 and 50 nM miRNA according to each manufacturer's protocol. The amount of PTK9 mRNA was measured relative to 18s rRNA levels using qRT-PCR and then normalized to the mRNA levels of the negative control, 48 hours post-transfection.  Error bars represent the standard deviation of triplicate wells.
 
Close